Application of hematoporphyrin derivative combined chemical drug in liver cancer treatment

• Main Authors: LI ZENG, YANG GUOHONG, YANG GUANGSHAN, FAN GAOFEI, JI LIJUN, ZHANG TENGYUE, SUN JIN, QIAN LITING, HE JING, WANG MIN, FAN PINGSHENG, HUANG JIN, WANG XU, LIU MIAO, FANG PING, HE YIFU, TANG LILI, WANG GUOXING, LIU YABEI, WENG CHENGTAO, ZHAO YONGXIN, WU YANG, LIU TONGTONG, DUAN QIAOHONG
• Format: Patent
• Language: Chinese; English
• Published: 16.03.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention belongs to the field of medicine for increasing the sensitivity of chemotherapeutic drugs, and particularly relates to application of a hematoporphyrin derivative A2 of a hematoporphyrincombined verapamil fragment in tolerance and sensitization of liver cancer reverse chemotherapeutic drugs. The hematoporphyrin derivative A2 has the effect of inhibiting liver cancer cell proliferation of sensitization chemotherapeutic drugs of different degrees, and the hematoporphyrin derivative A2 can be developed into a sensitizer or a reverse drug-resistant agent of the chemotherapeutic drugs and used for treating liver cancer patients. 本发明属于增加化疗药物敏感性的医药学领域，具体涉及一种血卟啉骈合维拉帕米片段血卟啉衍生物A2在肝癌逆转化疗药物的耐受与增敏的用途。血卟啉衍生物A2具有不同程度的增敏化疗药物抑制肝癌细胞增殖作用，表明血卟啉衍生物A2能够发展成为化疗药物的增敏剂或者逆转耐药剂，用于肝癌患者的治疗。